TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer t
herapy.
Hormone-refractory prostate cancer is incurable, and patients with this disease have few treatment options. Dysregulation of the androgen receptor (AR) is a hallmark of this incurable cancer. Molecular changes during cancer enhance AR sensitivity or permit AR activation by antiestrogen so that pro…